Market Place
Sourcing Support
Scribe Validates CRISPR Tech for Cardiometabolic Disease at AHA
25 Nov 2024 //
BUSINESSWIRE
Scribe Therapeutics to Present Preclinical CRISPR Data at AHA
30 Oct 2024 //
BUSINESSWIRE
Scribe In Vivo Gene Editing, Epigenetic Editing At ASGCT
10 May 2024 //
BUSINESSWIRE
Scribe At ASGCT On CRISPR Genome, Epigenome Editing
22 Apr 2024 //
BUSINESSWIRE
Scribe to Participate in the Leerink Partners Global Biopharma Conference
06 Mar 2024 //
BUSINESSWIRE
Scribe Therapeutics Expands In Vivo Collaboration with Sanofi to Second Target
03 Jan 2024 //
BUSINESSWIRE
Scribe to Present at the 42nd Annual J.P. Morgan Healthcare Conference
02 Jan 2024 //
BUSINESSWIRE
Scribe Therapeutics Appoints Dr. Aarif Khakoo as Chief Scientific Officer
20 Dec 2023 //
BUSINESSWIRE
Sanofi licenses CRISPR enzyme in bid to develop safer, simpler sickle cell cure
18 Jul 2023 //
BUSINESSWIRE
Scribe Therapeutics to Participate in Upcoming Investor Conferences in May and June
22 May 2023 //
BUSINESSWIRE
Scribe Therapeutics Presents Data on its X-Editing Technologies at ASGCT
19 May 2023 //
BUSINESSWIRE
Scribe`s CRISPR tech Prevails with new $1.5B Lilly biobucks deal
17 May 2023 //
FIERCE BIOTECH
Scribe Therapeutics Announces Oral Presentation at 2023 (ASGCT) Annual Meeting
02 May 2023 //
BUSINESSWIRE
Scribe Therapeutics to Participate in Guggenheim Healthcare Talks
31 Mar 2023 //
BUSINESSWIRE
Scribe Therapeutics to Participate in Four Upcoming Conferences
17 Nov 2022 //
BUSINESSWIRE
Scribe Therapeutics to Participate in Upcoming Investor Conferences
29 Sep 2022 //
BUSINESSWIRE
Sanofi and Jennifer Doudna-Founded Scribe Ink $1B CRISPR Cell Therapy Deal
28 Sep 2022 //
BIOSPACE
Scribe Tx to Participate in SVB Securities Biopharma Private Company Connect
15 Jul 2022 //
BUSINESSWIRE
Biogen takes another dip into Scribe gene therapy collab
03 May 2022 //
FIERCEBIOTECH
Scribe Tx to Participate in Upcoming Goldman Sachs The New Guard
01 Apr 2022 //
BUSINESSWIRE
Scribe Tx Appoints David Parrot as CFO and George Manning as Controller
09 Mar 2022 //
BUSINESSWIRE
Scribe Therapeutics Raises $100M Series B Financing to Further Develop
31 Mar 2021 //
BUSINESSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.